Overall, our study demonstrates the feasibility and safety of editing TILs by ABE and indicates that dual KO of TIM3 and TIGIT in TILs derived from both melanoma and ovarian cancer warrants further investigation for potential clinical translation. This evidence concerns the gene TIGIT and ovarian carcinoma.